The NK1 receptor antagonist serlopitant for treatment of chronic pruritus

Sonja Ständer, Mary C. Spellman, Paul Kwon, Gil Yosipovitch

Research output: Contribution to journalArticle

Abstract

Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.

Original languageEnglish (US)
JournalExpert Opinion on Investigational Drugs
DOIs
StatePublished - Jan 1 2019

Fingerprint

Neurokinin-1 Receptor Antagonists
Pruritus
Therapeutics
Prurigo
Safety
Neurokinin-1 Receptors
Expert Testimony
serlopitant
Tablets
Compliance
Epidemiology
Quality of Life

Keywords

  • Chronic nodular prurigo
  • chronic pruritus
  • neurokinin 1 receptor
  • NK receptor
  • prurigo nodularis
  • psoriasis
  • serlopitant

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. / Ständer, Sonja; Spellman, Mary C.; Kwon, Paul; Yosipovitch, Gil.

In: Expert Opinion on Investigational Drugs, 01.01.2019.

Research output: Contribution to journalArticle

@article{31293d32e2124784b84bace191c8540b,
title = "The NK1 receptor antagonist serlopitant for treatment of chronic pruritus",
abstract = "Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.",
keywords = "Chronic nodular prurigo, chronic pruritus, neurokinin 1 receptor, NK receptor, prurigo nodularis, psoriasis, serlopitant",
author = "Sonja St{\"a}nder and Spellman, {Mary C.} and Paul Kwon and Gil Yosipovitch",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/13543784.2019.1638910",
language = "English (US)",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - The NK1 receptor antagonist serlopitant for treatment of chronic pruritus

AU - Ständer, Sonja

AU - Spellman, Mary C.

AU - Kwon, Paul

AU - Yosipovitch, Gil

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.

AB - Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.

KW - Chronic nodular prurigo

KW - chronic pruritus

KW - neurokinin 1 receptor

KW - NK receptor

KW - prurigo nodularis

KW - psoriasis

KW - serlopitant

UR - http://www.scopus.com/inward/record.url?scp=85068610789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068610789&partnerID=8YFLogxK

U2 - 10.1080/13543784.2019.1638910

DO - 10.1080/13543784.2019.1638910

M3 - Article

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

ER -